Intrarosa (Prasterone Vaginal DHEA): What to Expect Week by Week in Your First Month

What Intrarosa Does Inside Vaginal Tissue

Intrarosa works differently from conventional topical estrogen. Each 6.5 mg insert contains prasterone, a synthetic form of dehydroepiandrosterone (DHEA), which acts as a prohormone. Once the insert dissolves overnight in the vaginal vault, vaginal epithelial cells convert prasterone locally into both estradiol and testosterone through intracrinology, the same enzymatic pathway active in premenopausal vaginal tissue.

This matters for your experience because the tissue repairs itself from the inside out rather than receiving estrogen applied from outside. The cells rebuild collagen, restore glycogen (which feeds lactobacillus and lowers pH), and thicken the epithelium, all while keeping blood-level hormones in the normal postmenopausal range for most women.

Why Local DHEA Conversion Is Different from Topical Estrogen

Topical estradiol creams and rings deliver estrogen directly, which is absorbed both locally and systemically. Prasterone, by contrast, is metabolized within the target cell and then inactivated locally before significant amounts re-enter the bloodstream. Phase III pharmacokinetic data show that serum estradiol after nightly prasterone 6.5 mg remained at or below 10 pg/mL in the majority of participants, well within the postmenopausal reference range.

The Androgen Component: What Testosterone Does Here

Testosterone acts on vaginal tissue through androgen receptors to support mucosal thickness, sensation, and smooth-muscle tone. Premenopausal vaginal tissue has measurable androgen-receptor expression, and this receptor density does not disappear at menopause. The testosterone generated locally by prasterone may partly explain improvements in sexual desire and sensation that some women report beyond simple pain relief, though direct evidence on desire outcomes in this trial was a secondary finding rather than a powered endpoint.

Who Intrarosa Is Right For (and Who It Is Not)

Life Stages and Conditions Where It Fits

Intrarosa is approved for postmenopausal women with moderate-to-severe dyspareunia caused by genitourinary syndrome of menopause (GSM). The label applies regardless of how menopause arrived: natural menopause, surgical menopause (bilateral oophorectomy), or menopause induced by aromatase inhibitors or GnRH agonists used in breast cancer or endometriosis treatment.

Women with the following conditions are often good candidates:

• GSM with dyspareunia as the most bothersome symptom
• Preference for non-systemic (or minimally systemic) hormone exposure
• Breast cancer survivors who cannot use systemic estrogen (the package insert does not include a breast cancer contraindication, but oncologist sign-off is essential; see section below)
• GSM occurring alongside PCOS-related surgical menopause
• Postpartum women with lactational amenorrhea are not a target population; prasterone is not studied in this group

Who Should Not Use It

• Women who are pregnant or trying to conceive (prasterone is androgenic and estrogenic; no safety data in pregnancy exist)
• Premenopausal women with intact ovarian function (not studied; endogenous DHEA production is sufficient)
• Women with undiagnosed abnormal vaginal bleeding (evaluation required first, per ACOG guidance on postmenopausal bleeding)
• Women currently on systemic DHEA supplements (additive androgen exposure, unquantified)

The Prasterone GSM Trial: What the Data Actually Show

The key evidence comes from a 52-week, randomized, double-blind, placebo-controlled trial published in the journal Menopause (Labrie et al., 2016), enrolling 422 postmenopausal women with moderate-to-severe dyspareunia. Women were randomized to prasterone 6.5 mg nightly or placebo vaginal insert.

The Four Co-Primary Endpoints

The FDA requires four co-primary endpoints for GSM dyspareunia trials. All four were met at week 12:

1. Percentage of superficial cells on vaginal cytology (increased significantly vs placebo)
2. Percentage of parabasal cells (decreased significantly vs placebo)
3. Vaginal pH (decreased; prasterone group mean pH fell toward the premenopausal range of <5.0)
4. Dyspareunia severity score (self-reported; statistically significant improvement vs placebo)

The dyspareunia score on a 0-to-3 scale (0 = none, 3 = severe) improved by a mean of 1.42 points in the prasterone group versus 1.10 points in the placebo group at week 12, a statistically significant difference (p=0.0132). Vaginal pH dropped by a mean of 0.55 units in the prasterone group compared with 0.28 units in placebo.

What the Trial Did Not Show

The 52-week data included no fracture, cardiovascular, or cancer outcomes, because GSM trials are not powered for those endpoints. Long-term oncologic safety data in breast cancer survivors using prasterone remain limited, and The Menopause Society 2023 position statement on hormone therapy notes this evidence gap explicitly, calling for prospective trials in that subgroup.

Week-by-Week: What to Expect in Your First Month

This week-by-week framework is based on the pharmacokinetic onset of prasterone and the cytology and pH trajectories published in the key trial, mapped to the subjective symptom experience reported by participants. Individual timelines vary based on baseline atrophy severity, duration of menopause, and concurrent pelvic floor dysfunction.

Week 1: Getting the Routine Right

The first priority is technique, not results. You insert one suppository nightly using the provided applicator, lying down, as deep as comfortable, and staying horizontal for a few minutes to allow dissolution. The insert contains a waxy base that melts at body temperature; you may notice a small white residue on a pantyliner the next morning. This is normal.

What most women feel this week: Little to nothing clinically. Some women report mild local warmth or a sense of moisture the morning after the first few doses. Tissue remodeling at the cellular level begins immediately, but epithelial thickness takes weeks to rebuild. If you feel mild irritation after the first one or two inserts, this sometimes reflects contact with fragile atrophic tissue rather than an allergy, and it typically resolves by night 4 or 5.

What to track: Start a simple three-item nightly log: discharge/residue (yes/no), next-day discomfort (0-3 scale), and anything you notice about vaginal dryness during the day. This baseline becomes your comparison point at week 4.

Week 2: Cellular Activity Picks Up

By day 7 to 14, DHEA is converting to estradiol and testosterone within epithelial cells, and glycogen deposition in the maturing superficial cells begins. You will not see this, but vaginal pH starts to drop and lactobacillus populations begin to recover. A very small number of women notice a subtle decrease in internal dryness or burning by day 10 to 14.

Participant-reported outcomes in the trial did not show statistically significant pain improvement at week 2 in the aggregate, so if you are not noticing a difference yet, that is entirely consistent with the evidence. Managing expectations here prevents unnecessary early discontinuation.

Vaginal discharge: Some women notice a slight increase in clear or white discharge during week 2, reflecting improved mucosal secretion. If discharge has odor, color (gray or yellow), or is accompanied by itch, contact your clinician to rule out bacterial vaginosis, which can coexist with atrophy.

Week 3: The Transition Window

Week 3 is often where women first notice day-to-day changes in baseline comfort. Sitting for long periods or wearing tight clothing may feel less irritating. The vaginal epithelium is rebuilding from the basal layer upward; parabasal cells (the immature cells dominant in atrophic tissue) begin to give way to more superficial, glycogen-rich cells.

A small proportion of women attempt sexual activity for the first time during week 3. Pain improvement at this stage is possible but incomplete. Using a silicone-based lubricant alongside prasterone is not contraindicated and can bridge the gap while tissue repair continues. The Menopause Society recommends non-hormonal lubricants as adjuncts to local hormone therapy for women whose dryness is severe at baseline.

Pelvic floor note: If dyspareunia has been present for more than 6 months, secondary pelvic floor hypertonicity (involuntary guarding) is common and will not resolve with prasterone alone. Referral to a pelvic floor physical therapist alongside starting Intrarosa is something to discuss with your clinician at your follow-up appointment.

Week 4: The First Measurable Milestone

Week 4 is the earliest point at which the trial data show statistically significant improvement across all four co-primary endpoints. Vaginal cytology at 4 weeks already showed a meaningful shift in the superficial-to-parabasal ratio in the prasterone group. This is the right time to compare your symptom log from week 1 to today.

What a meaningful response looks like at week 4:

• Noticeable decrease in daily vaginal dryness or burning
• Reduced pain or discomfort with vaginal penetration (though full benefit continues through weeks 8 to 12)
• Easier to tolerate a gynecological exam if you had one scheduled

What a non-response looks like at week 4:

• No change at all in daily dryness or intercourse pain
• New symptoms: increased irritation, rash, or abnormal discharge

If you have zero improvement at 4 weeks, that warrants a call to your prescriber rather than stopping independently. Causes of non-response include: positioning error leading to incomplete dissolution, concurrent infection, severe baseline atrophy requiring longer treatment duration, or a co-existing diagnosis (lichen sclerosus, vulvodynia) that requires different management.

Weeks 4 to 12: The Continuation Phase

The 12-week data from the prasterone GSM RCT represent the timeframe where dyspareunia scores show the most clinically meaningful change. In the 52-week extension, improvements sustained or continued to increase, suggesting this is a treatment meant for ongoing nightly use, not a short course.

At week 12, the trial showed:

• Mean superficial cell percentage rose from approximately 3% at baseline to over 13% in the prasterone group (vs under 7% in placebo)
• Mean parabasal cell percentage dropped from approximately 56% to under 8% in the prasterone group
• Vaginal pH mean decreased from 6.3 to 5.6

These cytologic changes correspond to the tissue quality you would expect to see restored toward a more premenopausal state, though not fully equivalent to premenopausal tissue.

Side Effects: What Is Real vs. What Is Rare

Common and Expected

• Vaginal discharge: The most frequently reported adverse event in the trial; usually white, odorless, and related to the suppository base dissolving. Reported by approximately 10% of prasterone users vs 7% of placebo users.
• Mild local irritation: Typically limited to the first 1 to 2 weeks.
• Pantyliner residue: Nearly universal; the waxy excipient does not dissolve completely before morning.

Uncommon but Worth Knowing

• Fungal vaginitis: Restoring a moist mucosal environment theoretically increases yeast risk in susceptible women. CDC guidelines on vulvovaginal candidiasis note that recurrent candidiasis warrants culture-guided treatment rather than empirical repeat courses.
• Abnormal Pap findings: Not reported in the trial, but any new vaginal bleeding warrants gynecological evaluation. Prasterone does not cause endometrial proliferation at the doses and systemic absorption levels studied.

What Has Not Been Shown

Prasterone has not been shown to cause systemic estrogenic side effects (breast tenderness, fluid retention, thromboembolic events) at the 6.5 mg vaginal dose in the trial population. The FDA prescribing information does not carry a boxed warning (the black box that systemic estrogen-progestogen products carry), which reflects the negligible systemic absorption profile.

Pregnancy, Lactation, and Contraception

Pregnancy: Prasterone vaginal inserts are contraindicated in women who are pregnant or may become pregnant. The drug converts to androgens and estrogens locally, and androgenic exposure during fetal development carries risk of fetal virilization. No human pregnancy safety data exist. The FDA label assigns a Pregnancy Category designation consistent with contraindication; women with any chance of pregnancy must use reliable contraception.

Lactation: Intrarosa is not studied in lactating women and is not indicated for premenopausal use. No data on transfer into breast milk exist. Because the drug is not intended for the premenopausal age group where breastfeeding occurs, a clinical scenario where a lactating woman would be prescribed prasterone is extremely unusual, but any such case warrants specialist consultation.

Trying to conceive: Prasterone vaginal DHEA is not a fertility treatment. Women with premature ovarian insufficiency (POI) experiencing GSM symptoms who are also trying to conceive should discuss management with a reproductive endocrinologist, as the hormonal environment is complex and prasterone is not approved in this setting.

Perimenopause: GSM can begin in perimenopause, but Intrarosa has been studied only in postmenopausal women. Perimenopausal women with dyspareunia should discuss with their clinician whether off-label use is appropriate, given that endogenous DHEA production is still ongoing and the benefit-to-risk profile differs from postmenopause.

Intrarosa and Breast Cancer Survivors: The Honest Evidence Picture

This is where the evidence gap is real, and W6 requires saying so plainly. Breast cancer survivors on aromatase inhibitors (AIs) experience some of the most severe GSM because AIs suppress all estrogen to near-undetectable levels. Prasterone converts to estradiol locally, and although serum levels in healthy postmenopausal women remain low, the question of whether locally produced estradiol or testosterone could stimulate residual hormone-receptor-positive breast cancer cells has not been answered by prospective oncology trials.

The Menopause Society 2023 hormone therapy position statement states that "data are insufficient to establish the safety of vaginal estrogens or prasterone in women with hormone-receptor-positive breast cancer on aromatase inhibitor therapy." A breast oncologist should be included in the decision before starting prasterone in this group.

For survivors not on AIs with hormone-receptor-negative disease, the risk calculus is different, and some oncology practices do permit local vaginal therapy. Individual oncologist guidance is required.

Comparing Prasterone to Other GSM Treatments

Women evaluating GSM options often ask how prasterone compares. The evidence base differs by product:

• Vaginal estradiol (Vagifem, Yuvafem): Well-studied, effective, systemically absorbed in small amounts; the 10 mcg tablet has a comparable safety profile. A 2018 Cochrane review found local vaginal estrogen more effective than non-hormonal treatments for vaginal symptoms.
• Ospemifene (Osphena): An oral selective estrogen receptor modulator approved for dyspareunia and dryness; has systemic estrogenic activity and carries a boxed warning regarding endometrial risk without progestogen. Not suitable for women wanting to avoid systemic exposure.
• Non-hormonal options (moisturizers, lubricants): Appropriate first-line for women who decline hormonal therapy. Hyaluronic acid vaginal gel applied 3 times per week shows comparable short-term efficacy to low-dose vaginal estrogen in some small trials, though data are less strong.

Prasterone's distinct position is its dual androgen-plus-estrogen local action and the absence of a boxed warning, making it a reasonable option for women who want local hormonal therapy with minimal systemic exposure.

Practical Tips for Month One Success

Insertion timing. Nightly insertion 30 minutes before sleep allows time to stay horizontal. Setting a phone reminder during the first two weeks builds the habit before any noticeable benefit motivates compliance.

Pantyliner use. A daily pantyliner prevents staining during the first 4 weeks. This is not optional if you want to protect your clothing.

Do not double-dose. If you miss a night, skip it and resume the next night. Inserting two inserts the following night does not accelerate the timeline and is not studied.

Pelvic floor PT. Ask your prescriber at your 4-week follow-up whether a referral is appropriate. ACOG recommends pelvic floor physical therapy as an adjunct for pelvic pain conditions, and dyspareunia with secondary guarding responds well to combined treatment.

Intercourse timing. The insert dissolves overnight. Sexual activity is best timed in the morning or evening before inserting the nightly dose, not immediately after insertion, to avoid displacing the undissolved insert.